Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Background Increased levels of the tumour necrosis factor (TNF) -ligand APRIL (A Proliferation ... In addition, mice were analysed for histological signs of arthritis. Anticollagen antibody titers ...

In general, anti-TNF therapy should not be initiated in the presence of severe infections and should be interrupted when these occur during treatment; however, they can be reintroduced once ...

Monitoring individuals with robust and clinically validated tests for both drugs and antidrug antibodies is the only way to ensure cost-effective, long-term use of anti-TNF-α biopharmaceuticals.

This Phase 1 study evaluated the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody ... intervention using steroids and TNF-alpha inhibitors. No Grade 4 or 5 TRAEs ...

Those who used anti-TNF and anti-IL-17 drugs had a lower incidence and risk for Parkinson’s vs. those who did not. Patients treated with anti-IL-17 only had a lower risk for PD compared with ...

Despite action by the justices, the law remains on hold Challengers say Trump administration may decide the matter Jan 23 (Reuters) - The U.S. Supreme Court on Thursday declined to block ...